The GIPR signaling pathway is associated with body fat accumulation. GMA106, an M-Body targeting both GIPR and GLP-1R, decreases appetite and accumulation of body fat through the regulation of both pathways. With a prolonged half-life, GMA106 may achieve a better dosing regimen (weekly or monthly) and a higher patient adherence.
In pre-clinical studies GMA106 showed excellent efficacy in reducing body weight, particularly the content of body fat, and it may become a very effective drug for obesity ，NASH and T2DM.
GMA106 is currently in phase Ⅰ trial in Australia.